NCT05272839

Brief Summary

Type 2 diabetes patients often do not reach desired control of glycemia despite guidance on changing lifestyle and diet as well as the use of conventional anti-diabetic medication. Parallely in recent years, an array of comparative clinical studies have demonstrated the anti-diabetic effect of more than 10 common spices and food products. Objectives: to evaluate whether proposing a choice of spices and foods products with hypoglycemic effect to diabetic patients can help better control diabetes.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
124

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2022

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 17, 2022

Completed
21 days until next milestone

First Posted

Study publicly available on registry

March 10, 2022

Completed
22 days until next milestone

Study Start

First participant enrolled

April 1, 2022

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
Last Updated

March 10, 2022

Status Verified

February 1, 2022

Enrollment Period

1.2 years

First QC Date

February 17, 2022

Last Update Submit

February 28, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • Decrease of ≥ 0.5mmol/L in FPG

    Percentage of patients in each group reaching a decrease of ≥ 0.5mmol/L in FPG over 12 weeks

    12 weeks

  • Decrease of ≥ 0.5 points of percentage of HbA1c

    Percentage of patients in each group reaching a decrease of ≥ 0.5 points of percentage from the baseline value in HbA1c over 12 weeks

    12 weeks

Secondary Outcomes (5)

  • Mean change of FPG

    12 weeks

  • Target glycemia

    12 weeks

  • Weight

    12 weeks

  • Mean change of HbA1c

    12 weeks

  • Blood pressure

    12 weeks

Study Arms (2)

Hypoglycemic food group

EXPERIMENTAL

The patient will choose 2 food products clinically validated against diabetes, at the same dosage and the same mode of preparation as in the reference clinical trials. This will be done additionally to healthcare advice and standard medication if any.

Dietary Supplement: Hypoglycemic food group

Control group

PLACEBO COMPARATOR

The control group will receive only dietary advice and standard medication if any.

Dietary Supplement: Control group

Interventions

Hypoglycemic food groupDIETARY_SUPPLEMENT

A booklet with 4 common food products, clinically validated against diabetes, with instructions for use will be presented to the diabetic patient. The selected food products have been assessed as anti-diabetic for humans through at least one fair randomized comparative clinical trial, with a follow-up of several weeks or months. While continuing to take his/her standard medication if any, the patient will be encouraged to follow his/her preferences within the established list of foods and spices: he is expected to choose 2 plants from the list and to consume each of them every day during the whole duration of the trial (12weeks).

Hypoglycemic food group
Control groupDIETARY_SUPPLEMENT

The control group will receive only lifestyle and dietary recommendations.

Control group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 diabetes patients with poorly controlled glycemia, i.e. at least one of the following measurements:
  • Fasting plasma glucose (FPG) values ≥ 7.0 mmol/L (126 mg/dl), or 2-h post-load plasma glucose ≥ 11.1 mmol/L (200 mg/dl), or HbA1c \> 6.5% (48 mmol/mol); or a random blood glucose ≥ 11.1 mmol/L (200 mg/ dl), despite ≥ 3 months usual care (lifestyle + medication if applicable).

You may not qualify if:

  • Severe and unstable complications of diabetes: end-organ damage such as nephropathy, retinopathy, neuropathy, etc...
  • Patients with rapid insulin,
  • Any health condition that requires urgent attention,
  • Patients with a cognitive or sensory impairment that may prevent conducting the interview,
  • HbA1c \> 11.5%
  • Pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Willcox ML, Elugbaju C, Al-Anbaki M, Lown M, Graz B. Effectiveness of Medicinal Plants for Glycaemic Control in Type 2 Diabetes: An Overview of Meta-Analyses of Clinical Trials. Front Pharmacol. 2021 Nov 26;12:777561. doi: 10.3389/fphar.2021.777561. eCollection 2021.

    PMID: 34899340BACKGROUND

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Bertrand Graz, MD, MPH

    Antenna Foundation

    STUDY DIRECTOR

Central Study Contacts

Praew Kotruchin, Prof

CONTACT

Anne-Laure Cavin, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: At the first visit, patients will be randomly assigned to control group or intervention group.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 17, 2022

First Posted

March 10, 2022

Study Start

April 1, 2022

Primary Completion

July 1, 2023

Study Completion

July 1, 2024

Last Updated

March 10, 2022

Record last verified: 2022-02

Data Sharing

IPD Sharing
Will share

IPD will be kept in a safe location in Khon Kaen University hospital. It will be available in an anonymous manner upon request and after deidentification.

Shared Documents
STUDY PROTOCOL
Time Frame
April 2023 up to April 2033
Access Criteria
It will be accessible to any researchers or reviewers who might review the data and perhaps perform some new data analysis. The decision will be in the hands of the Principal investigator and colleagues in Khon Kaen University, plus health and ethical authorities following legislation.